FEM-PrEP

Profile photo
Profile photo
Profile photo
Profile photo
Profile photo
Profile photo
Profile photo
Profile photo

Women shown in the pictures are not FEM-PrEP participants

FEM-PrEP

  • FEM-PrEP was a randomized, placebo-controlled trial to assess the safety and effectiveness of a daily oral dose of tenofovir disoproxil fumarate and emtricitabine for HIV prevention among women.
    Read more

Publications

  • Click here to learn about FEM-PrEP manuscripts related to adherence, clinical outcomes, community engagement, contraception and pregnancy, laboratory, participant recruitment, risk perceptions and sexual behaviors, and PrEP rollout.
    Read more

Related Research & Information

  • FHI 360 and others are currently or have recently conducted complementary research on ARV-based HIV prevention products.
    Read more